Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.

Travers M, Brown SM, Dunworth M, Holbert CE, Wiehagen KR, Bachman KE, Foley JR, Stone ML, Baylin SB, Casero RA Jr, Zahnow CA.

Cancer Res. 2019 Jul 1;79(13):3445-3454. doi: 10.1158/0008-5472.CAN-18-4018. Epub 2019 May 14.

PMID:
31088836
2.

Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic.

Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8583-E8584. doi: 10.1073/pnas.1811015115. Epub 2018 Sep 4. No abstract available.

3.

A mechanism of T cell dependent selection of antigen engaged Germinal Center B cells.

Krishna V, Bachman KE.

PLoS One. 2018 Aug 23;13(8):e0200241. doi: 10.1371/journal.pone.0200241. eCollection 2018.

4.

Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes.

Ai R, Laragione T, Hammaker D, Boyle DL, Wildberg A, Maeshima K, Palescandolo E, Krishna V, Pocalyko D, Whitaker JW, Bai Y, Nagpal S, Bachman KE, Ainsworth RI, Wang M, Ding B, Gulko PS, Wang W, Firestein GS.

Nat Commun. 2018 May 15;9(1):1921. doi: 10.1038/s41467-018-04310-9.

5.

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.

Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA.

Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990. doi: 10.1073/pnas.1712514114. Epub 2017 Dec 4.

6.

Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.

Hou W, Qin X, Zhu X, Fei M, Liu P, Liu L, Moon H, Zhang P, Greshock J, Bachman KE, Ye BC, Wang H, Zang CY.

Oncol Rep. 2013 Aug;30(2):707-14. doi: 10.3892/or.2013.2500. Epub 2013 May 27.

PMID:
23708506
7.

Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma.

Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Kang J, Qin CY.

Exp Ther Med. 2013 Jan;5(1):57-64. Epub 2012 Oct 15.

8.

Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma.

Zhu X, Qin X, Fei M, Hou W, Greshock J, Bachman KE, Wooster R, Kang J, Qin CY.

Int J Mol Sci. 2012;13(8):9980-91. doi: 10.3390/ijms13089980. Epub 2012 Aug 10.

9.

Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth.

van den Heuvel AP, Jing J, Wooster RF, Bachman KE.

Cancer Biol Ther. 2012 Oct;13(12):1185-94. doi: 10.4161/cbt.21348. Epub 2012 Aug 15.

10.

Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.

Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH.

Clin Cancer Res. 2012 Jun 15;18(12):3462-9. doi: 10.1158/1078-0432.CCR-11-2696. Epub 2012 Mar 15.

11.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9. doi: 10.1073/pnas.1018854108. Epub 2011 Oct 14.

12.

Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.

Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17773-8. doi: 10.1073/pnas.1110969108. Epub 2011 Oct 10.

13.

Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response.

Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH, Weber DJ, Bachman KE.

Oncogene. 2010 Aug 19;29(33):4715-24. doi: 10.1038/onc.2010.220. Epub 2010 Jun 21.

14.

Molecular target class is predictive of in vitro response profile.

Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, Hardwicke MA, Wooster R.

Cancer Res. 2010 May 1;70(9):3677-86. doi: 10.1158/0008-5472.CAN-09-3788. Epub 2010 Apr 20.

15.

Catalogue, cause, complexity and cure; the many uses of cancer genome sequence.

Wooster R, Bachman KE.

Curr Opin Genet Dev. 2010 Jun;20(3):336-41. doi: 10.1016/j.gde.2010.03.007. Epub 2010 Apr 9. Review.

PMID:
20382522
16.

Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells.

Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, Martin SS, Weber DJ, Bachman KE.

Cancer Res. 2009 Nov 1;69(21):8275-83. doi: 10.1158/0008-5472.CAN-09-1067. Epub 2009 Oct 20.

17.

Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2835-40. doi: 10.1073/pnas.0813351106. Epub 2009 Feb 5.

18.

Identification and validation of human DNA ligase inhibitors using computer-aided drug design.

Zhong S, Chen X, Zhu X, Dziegielewska B, Bachman KE, Ellenberger T, Ballin JD, Wilson GM, Tomkinson AE, MacKerell AD Jr.

J Med Chem. 2008 Aug 14;51(15):4553-62. doi: 10.1021/jm8001668. Epub 2008 Jul 17.

19.

Tamoxifen-stimulated growth of breast cancer due to p21 loss.

Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, Bachman KE, Park BH.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):288-93. Epub 2007 Dec 27.

20.

Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, Park BH.

Cancer Res. 2007 Sep 15;67(18):8460-7.

21.

P21 gene knock down does not identify genetic effectors seen with gene knock out.

Karakas B, Weeraratna AT, Abukhdeir AM, Konishi H, Gustin JP, Vitolo MI, Bachman KE, Park BH.

Cancer Biol Ther. 2007 Jul;6(7):1025-30.

22.

The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation.

Vitolo MI, Anglin IE, Mahoney WM Jr, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A.

Cancer Biol Ther. 2007 Jun;6(6):856-63. Epub 2007 Mar 1.

PMID:
17438369
23.

High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.

Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE, Kern SE.

Cancer Res. 2007 Mar 1;67(5):2169-77.

24.

Persistent mismatch repair deficiency following targeted correction of hMLH1.

Weiss MB, Vitolo MI, Baerenfaller K, Marra G, Park BH, Bachman KE.

Cancer Gene Ther. 2007 Jan;14(1):98-104. Epub 2006 Nov 3.

PMID:
17082796
25.

MCT-1 protein interacts with the cap complex and modulates messenger RNA translational profiles.

Reinert LS, Shi B, Nandi S, Mazan-Mamczarz K, Vitolo M, Bachman KE, He H, Gartenhaus RB.

Cancer Res. 2006 Sep 15;66(18):8994-9001.

26.

The consensus coding sequences of human breast and colorectal cancers.

Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE.

Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.

27.

Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells.

Karakas B, Weeraratna A, Abukhdeir A, Blair BG, Konishi H, Arena S, Becker K, Wood W 3rd, Argani P, De Marzo AM, Bachman KE, Park BH.

Oncogene. 2006 Sep 7;25(40):5561-9. Epub 2006 Apr 17.

PMID:
16619041
28.

Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells.

Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo MI, Bachman KE, Park BH.

Breast Cancer Res Treat. 2006 Sep;99(1):23-33. Epub 2006 Mar 16.

PMID:
16541319
29.

Mutation of the PIK3CA oncogene in human cancers.

Karakas B, Bachman KE, Park BH.

Br J Cancer. 2006 Feb 27;94(4):455-9. Review.

30.

De novo CpG island methylation in human cancer cells.

Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB, Schuebel KE.

Cancer Res. 2006 Jan 15;66(2):682-92.

31.

Distinct epigenetic changes in the stromal cells of breast cancers.

Hu M, Yao J, Cai L, Bachman KE, van den Brûle F, Velculescu V, Polyak K.

Nat Genet. 2005 Aug;37(8):899-905. Epub 2005 Jul 10.

PMID:
16007089
32.

Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells.

Bachman KE, Sager J, Cheong I, Catto M, Bardelli A, Park BH, Vogelstein B, Carotti A, Kinzler KW, Lengauer C.

Mol Cancer Ther. 2005 Jun;4(6):1026-30.

33.

Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter.

Bachman KE, Park BH.

Curr Opin Oncol. 2005 Jan;17(1):49-54. Review.

PMID:
15608513
34.

The PIK3CA gene is mutated with high frequency in human breast cancers.

Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH.

Cancer Biol Ther. 2004 Aug;3(8):772-5. Epub 2004 Aug 26. Erratum in: Cancer Biol Ther. 2005 Feb;4(2):133.

PMID:
15254419
35.

p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells.

Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH.

Cancer Biol Ther. 2004 Feb;3(2):221-5. Epub 2004 Feb 1.

PMID:
14726675
36.

The methyl-CpG binding protein MBD1 interacts with the p150 subunit of chromatin assembly factor 1.

Reese BE, Bachman KE, Baylin SB, Rountree MR.

Mol Cell Biol. 2003 May;23(9):3226-36.

37.

Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene.

Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B.

Cancer Cell. 2003 Jan;3(1):89-95.

38.

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.

Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B.

Nature. 2002 Apr 4;416(6880):552-6.

PMID:
11932749
39.

Enzymatic regional methylation assay: a novel method to quantify regional CpG methylation density.

Galm O, Rountree MR, Bachman KE, Jair KW, Baylin SB, Herman JG.

Genome Res. 2002 Jan;12(1):153-7.

40.

Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin.

Bachman KE, Rountree MR, Baylin SB.

J Biol Chem. 2001 Aug 24;276(34):32282-7. Epub 2001 Jun 26.

41.

DNA methylation, chromatin inheritance, and cancer.

Rountree MR, Bachman KE, Herman JG, Baylin SB.

Oncogene. 2001 May 28;20(24):3156-65. Review.

42.

Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer.

Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG.

Hum Mol Genet. 2001 Apr;10(7):687-92. Review.

PMID:
11257100
44.

DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci.

Rountree MR, Bachman KE, Baylin SB.

Nat Genet. 2000 Jul;25(3):269-77.

PMID:
10888872
45.

Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers.

Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR.

Cancer Res. 1999 Feb 15;59(4):798-802.

46.

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.

Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB.

Nat Genet. 1999 Jan;21(1):103-7.

PMID:
9916800

Supplemental Content

Loading ...
Support Center